Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia | Zendy

Qin Lü | Zendy; JeanJacques Rouby | Zendy; P F Laterre | Zendy; Philippe Eggimann | Zendy; Anthony Dugard | Zendy; Evangelos J. GiamarellosBourboulis | Zendy; E. Mercier | Zendy; Jorge Garbino | Zendy; CharlesÉdouard Luyt | Zendy; Jean Chastre | Zendy; V. Georgescu-Kyburz | Zendy; Michael P. Rudolf | Zendy; Valérie Gafner | Zendy; Hedvika Lazar | Zendy; H Koch | Zendy; Anna Rey-Perez | Zendy; Stefanie D. Krämer | Zendy; M. Tamm | Zendy

Open Access

Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia

Author(s) -

Qin Lü,

JeanJacques Rouby,

P F Laterre,

Philippe Eggimann,

Anthony Dugard,

Evangelos J. GiamarellosBourboulis,

E. Mercier,

Jorge Garbino,

CharlesÉdouard Luyt,

Jean Chastre,

V. Georgescu-Kyburz,

Michael P. Rudolf,

Valérie Gafner,

Hedvika Lazar,

H Koch,

Anna Rey-Perez,

Stefanie D. Krämer,

M. Tamm

Publication year - 2011

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkr046

Subject(s) - pseudomonas aeruginosa , pneumonia , medicine , immunotherapy , intensive care medicine , pharmacokinetics , immunology , microbiology and biotechnology , immune system , bacteria , pharmacology , biology , genetics

Nosocomial Pseudomonas aeruginosa pneumonia remains a major concern in critically ill patients. We explored the potential impact of microorganism-targeted adjunctive immunotherapy in such patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research